Skip Navigation

Great Point Partners

Bernhard Hampl, Ph.D.

Board Member
Email: Dr. Bernhard Hampl

Dr. Hampl joined Great Point Partners’ Advisory Board in 2011 and is Co-Chairman of the Board of Directors of our portfolio companies Cytovance Biologics and Softbox Systems. Dr. Hampl is President of BKH Pharma-Services, LLC and currently on the Board of Chenwerth Inc., a leading Active Pharmaceutical Ingredient ("API") provider to the pharmaceutical industry. Previously, Dr. Hampl was Executive Chairman of the Board of APP / Fresenius Kabi U.S. from 2009 to 2012. He is also a minority investor in several start-up pharmaceutical companies.

Prior to that, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million.

Dr. Hampl earned a Ph.D. in Pharmaceutical Chemistry from the Ludwig Maximilian University of Munich, Germany, School of Chemistry and Pharmacy.

CEO Experience

  • Sandoz US-division of Novartis – biosimilar, biologic and generic pharmaceuticals
  • Eon Labs – specialty pharmaceuticals